Gene Amplification in Esophageal Adenocarcinomas and Barrett's with High-Grade Dysplasia

Clinical Cancer Research

Volumn 9, Issue 13, 2003, Pages 4819-4825

  Miller, Charles T ^a   Moy, Justin R ^a   Lin, Lin ^a   Schipper, Matthew ^a   Normolle, Daniel ^a   Brenner, Dean E ^a,b   Iannettoni, Mark D ^a   Orringer, Mark B ^a   Beer, David G ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT;

A1B1 GENE; ADENOCARCINOMA; AKT1 GENE; AMPLICON; ARTICLE; BARRETT ADENOCARCINOMA; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SCREENING; CARCINOGENESIS; CCND1 GENE; CCNE1 GENE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DRUG TARGETING; DYKR2 GENE; EARLY DIAGNOSIS; EGFR GENE; EPITHELIUM DYSPLASIA; ERBB2 GENE; ESOPHAGUS; FEMALE; GATA4 GENE; GENE; GENE AMPLIFICATION; HISTOPATHOLOGY; HNF3 ALPHA GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IGF1R GENE; KRAS GENE; MAJOR CLINICAL STUDY; MALE; ONCOGENE C MYC; PIK3CA GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SOUTHERN BLOTTING; TREATMENT PLANNING;

ADENOCARCINOMA; BARRETT ESOPHAGUS; BLOTTING, SOUTHERN; CELL LINE, TUMOR; ESOPHAGEAL NEOPLASMS; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 0142250376     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Skinner, D. B. Surgical treatment for esophageal carcinoma. Semin. Oncol., 11: 136-143, 1984.
2. Spechler, S. J., and Goyal, R. K. Barrett's esophagus. N. Engl. J. Med., 315: 362-371, 1986.
3. Sjogren, R. W., Jr., and Johnson, L. F. Barrett's esophagus: a review. Am. J. Med., 74: 313-321, 1983.
4. Altorki, N. K., and Skinner, D. B. Adenocarcinoma in Barrett's esophagus. Semin. Surg. Oncol., 6: 274-278, 1990.
5. Ferguson, M. K., and Naunheim, K. S. Resection for Barrett's mucosa with high-grade dysplasia: implications for prophylactic photodynamic therapy. J. Thorac. Cardiovasc. Surg., 114: 824-829, 1997.
6. Edwards, M. J., Gable, D. R., Lentsch, A. B., and Richardson, J. D. The rationale for esophagectomy as the optimal therapy for Barrett's esophagus with high-grade dysplasia. Ann. Surg., 223: 585-591, 1996.
7. Heitmiller, R. F., Redmond, M., and Hamilton, S. R. Barrett's esophagus with high-grade dysplasia: an indication for prophylactic esophagectomy. Ann. Surg., 224: 66-71, 1996.
8. Peters, J. H. The surgical management of Barrett's esophagus. Gastroenterol. Clin. N. Am., 26: 647-668, 1997.
9. Blount, P. L., Ramel, S., Raskind, W. H., Haggitt, R. C., Sanchez, C. A., Dean, P. J., Rabinovitch, P. S., and Reid, B. J. 17p allelic deletions and p53 protein overexpression in Barrett's adenocarcinoma. Cancer Res., 51: 5482-5486, 1991.
10. INK4α lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res., 61: 8284-8289, 2001.
11. Huang, Y., Boynton, R. F., Blount, P. L., Silverstein, R. J., Yin, J., Tong, Y., McDaniel, T. K., Newkirk, C., Resau, J. H., and Sridhara, R. Loss of heterozygosity involves multiple tumor suppressor genes in human esophageal cancers. Cancer Res., 52: 6525-6530, 1992.
12. Gonzalez, M. V., Artimez, M. L., Rodrigo, L., Lopez-Larrea, C., Menendez, M. J., Alvarez, V., Perez, R., Fresno, M. F., Perez, M. J., Sampedro, A., and Coto, E. Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma. J. Clin. Pathol., 50: 212-217, 1997.
13. Montesano, R., Hollsein, M., and Hainaul, P. Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: a review. Int. J. Cancer, 69: 225-235, 1996.
14. Hughes, S. J., Glover, T. W., Zhu, X. X., Kuick, R., Thoraval, D., Orringer, M. B., Beer, D. G., and Hanash, S. A. novel amplicon at 8p22-23 results in overexpression of cathepsin B in esophageal adenocarcinoma. Proc. Natl. Acad. Sci. USA, 95: 12410-12415, 1998.
15. Lin, L., Aggarwal, S., Glover, T. W., Orringer, M. B., Hanash, S., and Beer, D. G. A minimal critical region of the 8p22-23 amplicon in esophageal adenocarcinomas defined using sequence tagged site-amplification mapping and quantitative polymerase chain reaction includes the GATA-4 gene. Cancer Res., 60: 1341-1347, 2000.
16. Lin, L., Prescott, M. S., Zhu, Z., Singh, P., Chun, S. Y., Kuick, R. D., Hanash, S. M., Orringer, M., B., Glover, T. W., and Beer, D. G. Identification and characterization of a 19q12 amplicon in esophageal adenocarcinoma reveals cyclin E as the best candidate for this amplicon. Cancer Res., 60: 7021-7027, 2000.
17. Lin, L., Prescott, M. S., Orringer, M. B., van Dekken, H., Misek, D., Hanash, S., Glover, T. W., and Beer, D. G. Identification and fine-mapping the core amplified domain of a 3q26 amplicon in primary esophageal and lung cancers. Proc. Am. Assoc. Cancer Res., 42: 1032, 2001.
18. Miller, C. T., Aggarwal, S. A., Lin, T. K., Dagenais, S. L., Contreras, J. I., Orringer, M. B., Glover, T. W., Beer, D. G., and Lin, L. Amplification and overexpression of the dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 (DYRK2) gene in esophageal and lung adenocarcinomas. Cancer Res., 63: 4136-4143, 2003.
19. Lin, L., Miller, C. T., Contreras, J. I., Prescott, M. S., Dagenais, S. L., Wu, R., Yee, J., Orringer, M. B., Misek, D. E., Hanash, S. M., Glover, T. W., and Beer, D. G. The hepatocytes nuclear 3 α gene, HNF3α (FOXA1), on chromosome band 14q13 is amplified and over-expressed in esophageal and lung adenocarcinomas. Cancer Res., 62: 5273-5279, 2002.
20. Al-Kasspooles, M., Moore, J. H., Orringer, M. B., and Beer, D. G. Amplification and overexpression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. Int. J. Cancer, 54: 213-219, 1993.
21. Morgan, R. J., Newcomb, P. V., Hardwick, R. H., and Alderson, D. Amplification of cyclin D1 and MDM2 in oesophageal carcinoma. Eur. J. Surg. Oncol., 25: 364-367, 1999.
22. McKenna, B. J., and Appelman, H. D. Dysplasia of the gut. J. Clin. Gastroenterol., 34: 111-116, 2002.
23. Appelman, H. D., Kalish, R. J., Clancy, P. E., and Orringer, M. B. Distinguishing features of adenocarcinoma in Barrett's esophagus and in the gastric cardia. In: S. J. Spechler and R. K. Goyal (eds.), Barrett's Esophagus: Pathophysiology, Diagnosis, and Management, pp. 167-187. New York: Elsevier Science Publishing Co., Inc., 1985.
24. Hughes, S. J., Nambu, Y., Soldes, O. S., Hamstra, D., Rehemtulla, A., Iannettoni, M. D., Orringer, M. B., and Beer, D. G. Fas/APO-1 is not translocated to the cell membrane in esophageal adenocarcinoma. Cancer Res., 57: 5571-5578, 1997.
25. Stoner, G. D., Kaighn, M. E., Reddel, R. R., Resau, J. H., Bowman, D., Naito, Z., Matsukura, N., You, M., Galati, A. J., and Harris, C. C. Establishment and characterization of SV40 T-antigen immortalized human esophageal epithelial cells. Cancer Res., 51: 365-371, 1991.
26. Di Fiore, P. P., Pierce, J. H., Kraus, M. H., Segatto, O., King, C. R., and Aaronson, S. A. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science (Wash. DC), 237: 178-182, 1987.
27. Xu, Y. H., Ishii, S., Clark, A. J., Sullivan, M., Wilson, R. K., Ma, D. P., Roe, B. A., Merlino, G. T., and Pastan, I. Human epidermal-growth-factor-receptor cDNA is homologous to a variety of RNAs over-produced in A431 carcinoma cells. Nature (Lond.), 309: 806-810, 1984.
28. Ellis, R. W., DeFeo, D., Shih, T. Y., Gonda, M. A., Young, H. A., Tsuchida, N., Lowy, D. R., and Scolnick, E. M. The p21 src genes of Harvey and Kirsten sarcoma viruses originate from divergent members of a family of normal vertebrate genes. Nature (Lond.), 292: 506-511, 1981.
29. Anzick, S. L., Kononen, J., Walker, R. L., Azorsa, D. O., Tanner, M. M., Guan, X., Sauter, G., Kallioniemi, O., Trent, J. M., and Meltzer, P. M. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science (Wash. DC), 277: 965-968, 1997.
30. Shen-Ong, G. L. C., Keath, E. J., Picolli, S. P., and Cole, M. D. Novel myc oncogene RNA from abortive immunoglobulin-gene recombination in mouse plasmacytomas. Cell, 31: 443-452, 1982.
31. Gantz, I., Konda, Y., Yang, Y. K., Miller, D. E., Dierick, H. A., and Yamada, T. Molecular cloning of a novel receptor (CMKLR1) with homology to the chemotactic factor receptor. Cytogenet. Cell Genet., 74: 286-290, 1996.
32. Riegman, P. H. J., Vissers, K. J., Alers, J. C., Geelen, E., Hop, W. C. J., Tilanus, H. W., and van Dekken, H. Genomic alterations in malignant transformation of Barrett's esophagus. Cancer Res., 61: 3164-3170, 2001.
33. van Dekken, H., Geelen, E., Dinjens, W. N. M., Wihnhoven, B. P. L., Tilanus, H. W., Tanke, H. J., and Rosenberg, C. Comparative genomic hybridization of cancer of the gastroesophageal junction: deletion of 14q31-32. 1 discriminates between esophageal (Barrett's) and gastric cardia adenocarcinomas. Cancer Res., 59: 748-752, 1999.
34. Walch, A. K., Zitzelsberger, H. F., Bruch, J., Keller, G., Angermeier, D., Aubele, M. M., Mueller, J., Stein, H., Braselmann, H., Siewert, J. R., Hofler, H., and Werner, M. Chromosomal imbalances in Barrett's adenocarcinoma and the metaplasia-dysplasia-carcinoma sequence. Am. J. Pathol., 156: 555-566, 2000.
35. Masuda, H., Battifora, H., Yokota, J., Meltzer, S., and Cline, M. J. Specificity of proto-oncogene amplification in human malignant diseases. Mol. Biol. Med., 4: 213-227, 1987.
36. Schlegel, J., Stumm, G., Brandle, H., Merdes, A., Mechtersheimer, G., Hynes, N. E., and Kiessling, M. Amplification and differential expression of members of the erbB-gene family in human glioblastoma. J. Neurooncol., 22: 201-207, 1994.
37. Fajac, A., Benard, J., Lhomme, C., Rey, A., Duvillard, P., Rochard, F., Bernaudin, J. F., and Riou, G. c-erbB2 gene amplification and protein expression in ovarian epithelial tumors: evaluation of their respective prognostic significance in multivariate analysis. Int. J. Cancer, 64: 146-151, 1995.
38. Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novatny, W. F., Burchmore, M., Shak, S., Stewart, S. J., and Press, M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol., 20: 719-726, 2002.
39. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER/neu oncogene. Science (Wash. DC), 135: 177-182, 1987.
40. Kitagawa, Y., Masakazu, U., Ando, N., Ozawa, S., Shimizu, N., and Kitajima, M. Further evidence for prognostic significance of epidermal growth factor receptor gene amplification in patients with esophageal squamous cell carcinoma. Clin. Cancer Res., 2: 909-914, 1996.
41. Bani-Hani, K., Martin, I. G., Hardie, L. J., Mapstone, N., Briggs, J. A., Forman, D., and Wild, C. P. Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. J. Natl. Cancer Inst. (Bethesda), 92: 1316-1321, 2000.
42. Stein, C. K., Glover, T. W., Palmer, J. W., and Glisson, B. S. Direct correlation between FRA3B expression and cigarette smoking. Genes Chromosomes Cancer, 34: 333-340, 2002.
43. Hellman, A., Zlotorynski, E., Scherer, S. W., Cheung, J., Vincent, J. B., Smith, D. I., Trakhtenbrot, L., and Kerem, B. A role for common fragile site induction in amplification of human oncogenes. Cancer Cell, 1: 89-97, 2002.
44. Persons, D. L., Croughan, W. S., Borelli, K. A., and Cherian, R. Interphase cytogenetics of esophageal adenocarcinoma and precursor lesions. Cancer Genet. Cytogenet., 106: 11-17, 1998.
45. Sarbia, M., Arjumand, J., Wolter, M., Riefenberger, G., Heep, H., and Gabbert, H. E. Frequent c-myc amplification in high-grade dysplasia and adenocarcinoma in Barrett esophagus. Am. J. Clin. Pathol., 115: 835-840, 2001.